<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="8224">
  <!-- This xml conforms to an XML Schema at:
    http://clinicaltrials.gov/ct2/html/images/info/public.xsd
 and an XML DTD at:
    http://clinicaltrials.gov/ct2/html/images/info/public.dtd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on June 04, 2014</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>http://clinicaltrials.gov/show/NCT01899404</url>
  </required_header>
  <id_info>
    <org_study_id>UHN REB 12-5221-C</org_study_id>
    <nct_id>NCT01899404</nct_id>
  </id_info>
  <brief_title>MRI FDG PET Imaging Cervix</brief_title>
  <official_title>A Pilot Prospective Study of the Utility of Dynamic Contrast-Enhanced Magnetic Resonance Imaging (DCE-MRI), Diffusion Weighted MRI (DWI)and Positron Emission Tomography (PET) Imaging With 18F-Fluorodeoxyglucose (18FDG) in Brachytherapy for Cervix Cancer</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University Health Network, Toronto</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Princess Margaret Hospital, Canada</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>University Health Network, Toronto</source>
  <oversight_info>
    <authority>Canada: Ethics Review Committee</authority>
    <authority>Canada: Health Canada</authority>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The standard treatment for cervix cancer at Princess Margaret Hospital is external radiation
      with chemotherapy followed by internal radiation, called brachytherapy. Currently,
      brachytherapy treatment is planned on a type of Magnetic Resonance Imaging (MRI) called
      T2-weighted (T2W) MRI.

      The main purpose of this study is to determine whether the following imaging tests can
      visualize the tumor better for planning the brachytherapy treatment:

        1. special types of MRI called diffusion weighted MRI (DWI) and dynamic-contrast enhanced
           MRI (DCE-MRI); and

        2. an x-ray test called positron emission test (PET) performed with a sugar dye called
           FDG. MRI-guided brachytherapy is resource-intensive and not widely available.
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date>October 2012</start_date>
  <completion_date type="Anticipated">October 2014</completion_date>
  <primary_completion_date type="Anticipated">October 2014</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <study_design>Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Diagnostic</study_design>
  <primary_outcome>
    <measure>Target delineation in brachytherapy using standard T2-weighted MRI versus DCE-MRI, DWI and FDG-PET/CT imaging: gross tumor volume and high-risk clinical target volume in patients with cervical cancer</measure>
    <time_frame>2 years</time_frame>
    <safety_issue>No</safety_issue>
  </primary_outcome>
  <primary_outcome>
    <measure>Target delineation using standard MRI acquired during the last week of EBRT fused to planning CT versus full MRI-guided brachytherapy.</measure>
    <time_frame>2 years</time_frame>
    <safety_issue>No</safety_issue>
    <description>This objective will evaluate the potential for translation of this technique to centres with limited MRI access.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Follow-up imaging (MRI and 18FDG PET) versus the imaging done at the time of brachytherapy</measure>
    <time_frame>2 years</time_frame>
    <safety_issue>No</safety_issue>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Imaging techniques for visualizing the brachytherapy applicator.</measure>
    <time_frame>2 years</time_frame>
    <safety_issue>No</safety_issue>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">30</enrollment>
  <condition>Cervical Cancer Squamous Cell</condition>
  <arm_group>
    <arm_group_label>18-FDG PET/CT, DWI, DCE-MRI</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>18-FDG PET/CT, DWI, DCE-MRI</intervention_name>
    <description>All patients on this study will receive a Diffuse Weighted MRI and Dynamic Contrast Enhancing MRI during the routine MRI session on the day of brachytherapy (additional 10 minutes), and a FDG PET/CT scanning session on the day of brachytherapy.</description>
    <arm_group_label>18-FDG PET/CT, DWI, DCE-MRI</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. Age â‰¥ 18 years

          2. Histologic diagnosis of squamous cell carcinoma, adenocarcinoma or adenosquamous
             carcinoma of the cervix

          3. FIGO Stage IB - IVA

          4. Intention to treat using radiotherapy with or without concurrent cisplatin
             chemotherapy according to the current treatment policies of the PMH Gynecology Group

          5. Intention to treat with MR-guided brachytherapy as part of standard radiotherapy
             according to the current treatment policies of the PMH Gynecology Group

          6. No cytotoxic anti-cancer therapy for cervix cancer prior to study entry

          7. A negative urine or serum pregnancy test within the two week interval immediately
             prior to the first PET-CT imaging, in women of child-bearing age

          8. Ability to provide written informed consent to participate in the study

        Exclusion Criteria:

          1. Prior complete or partial hysterectomy

          2. Carcinoma of the cervical stump

          3. Inability to lie supine for more than 30 minutes

          4. Insulin-dependent diabetes mellitus

          5. Impaired kidney function with glomerular filtration rate &lt; 30

          6. Previous anaphylactic reaction to gadolinium or other contraindications to MR.
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Michael Milosevic, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>University Health Network, The Princess Margaret</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Michael Milosevic, MD</last_name>
    <phone>416 946 4501</phone>
    <phone_ext>2932</phone_ext>
    <email>Michael.Milosevic@rmp.uhn.on.ca</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Kathy Han, MD</last_name>
    <phone>416 946 4501</phone>
    <phone_ext>2919</phone_ext>
    <email>Kathy.Han@rmp.uhn.on.ca</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>University Health Network, The Princess Margaret</name>
      <address>
        <city>Toronto</city>
        <state>Ontario</state>
        <zip>M5G 2M9</zip>
        <country>Canada</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Michael Milosevic, MD</last_name>
      <phone>416 946 4501</phone>
      <phone_ext>2932</phone_ext>
      <email>Michael.Milosevic@rmp.uhn.on.ca</email>
    </contact>
    <contact_backup>
      <last_name>Kathy Han, MD</last_name>
      <phone>416 946 4501</phone>
      <phone_ext>2919</phone_ext>
      <email>Kathy.Han@rmp.uhn.on.ca</email>
    </contact_backup>
    <investigator>
      <last_name>Michael Milosevic, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Anthony Fyles, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>Canada</country>
  </location_countries>
  <verification_date>July 2013</verification_date>
  <lastchanged_date>July 10, 2013</lastchanged_date>
  <firstreceived_date>October 23, 2012</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Cervical Cancer</keyword>
  <keyword>PET Scan for cervix</keyword>
  <keyword>MRI for cervix</keyword>
  <is_fda_regulated>No</is_fda_regulated>
  <has_expanded_access>No</has_expanded_access>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Uterine Cervical Neoplasms</mesh_term>
    <mesh_term>Neoplasms, Squamous Cell</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
